China proposes the U.S. cut nuclear arsenals ‘to preserve world peace and security’ during UN-backed conference
Chinese Foreign Minister Wang Yi spoke Friday at the Conference on Disarmament in Beijing, recommending that the United States and Russia cut their nuclear arsenals. The United Nations recognizes the conference as a single multilateral disarmament negotiating forum for the international community.
Without naming them. Wang pointed to the U.S. and Russia as the focal point for disarmament as he addressed the conference of 65 nations. “The two largest nuclear-weapon States should further slash their nuclear arsenals in a verifiable, irreversible and legally binding manner to create conditions for the multilateral nuclear disarmament process,” Wang said.
Meanwhile, China is the fifth largest nuclear-weapon country. The United States is number one, followed by Russia, the United Kingdom and France. Just Wednesday, top Republican lawmakers wrote a letter to President Biden warning him that China is engaging in a nuclear build-up that could soon near “nuclear parity” with the U.S.
“Advancing international arms control, disarmament and non-proliferation processes is an important means to preserve world peace and security,” Wang said. He also implied that if the U.S. and Russia cut their arsenals, other nations would follow.
“A nuclear war cannot be won and must never be fought,” Wang said.
You can follow Jenny Goldsberry on Twitter @jennyjournalism.
You may like
FDA will work with China to import cancer drugs due to U.S. shortages
Earlier this week the United States Food and Drug Administration (FDA) announced it will be working to import chemotherapy drugs from, of all places, China. The drug, called Cisplatin, is to help “ramp up supply amidst rampant drug shortages in the U.S.” reports Foreign Desk News.
Foreign Desk News writes:
Cisplatin comes from drugmaker Qilu Pharmaceutical, which is marketed and produced in China but has not been approved by the FDA. According to a May 24 letter, Qilu will work with the Canadian-based drug company Apotex to import and distribute the medication, which will come in 50-milligram vials with Chinese labels.
“The FDA is responding to yet another generic drug shortage,” said Edmund F. Haislmaier, an expert in healthcare policy and markets at The Heritage Foundation. “The underlying cause of those shortages is that generic drugs have become low-margin commodity products,” he added.
Last week on Twitter, FDA commissioner Dr. Robert Califf said the partnership with Qilu Pharmaceutical is temporary but will provide patients with a potentially life-extending drug.
“The public should rest assured that we will continue all efforts within our authority to help the industry that manufactures and distributes these drugs meet all patient needs for the oncology drugs impacted by shortages,” Califf said.
The public should rest assured that we will continue all efforts within our authority to help the industry that manufactures and distributes these drugs meet all patient needs for the oncology drugs impacted by shortages. https://t.co/8XvOuJzSL4
— Dr. Robert M. Califf (@DrCaliff_FDA) June 3, 2023
Foreign Desk News adds:
The latest move by the FDA is sure to spark concern and debate in Congress, as lawmakers in the House and Senate have called on the Biden administration to de-couple the U.S. economy from the Chinese markets, given Beijing’s aggressive push to expand in the South-China Sea and eventually take over the island state of Taiwan. China has also spread illegal and dangerous synthetic opioids and fentanyl drugs across the U.S. southern border, resulting in the devastating deaths of many Americans.
You may like
Economy4 days ago
New York City Mayor Eric Adams Proposes Housing Asylum Seekers in Private Homes
education7 days ago
Documentary ‘What Is A Woman?’ exposes America’s true history of child exploitation
Economy4 days ago
Texas Gov Abbott aims to eliminate property taxes: ‘we must dream big’
Immigration3 days ago
Biden Administration to allow 40,000 asylum-seekers per month into US with mobile app